BT
Biolexis Therapeutics Inc.
SEC filingBiotechnology · Lehi, UT
Amount raised$1.6Msold at filing
Total offering$12M$10.4M still open
Investors in the raise2count reported to the SEC
FiledJun 3, 2026first sale May 20, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Tyler HartmannExecutive Officer
Hariprasad J. VankayalapatiDirector
James N. ClarkeDirector
Anthony N. SteveDirector
David J. BearssDirector
Executive officers, directors and promoters as listed on the Form D.